CClinicalTrials.gg
CompletedNCT02497430Updated Sep 15, 2016

Clinical Evaluation of the ARIES Group B Streptococcus (GBS) Assay

An observational study in Pregnancy and GBS, sponsored by Luminex Corporation. Completed at 5 sites in United States. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-09-15.

Sponsored by Luminex Corporation · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
918
Sex
Female
01

Study summary

The ARIES GBS Assay is a real-time PCR based qualitative test designed to detect Group B Streptococcus (GBS) nucleic acid from Lim Broth enriched vaginal-rectal specimen swabs obtained from pregnant women between 35 - 37 weeks gestation.

Read the detailed description

The ARIES GBS Assay is a real-time polymerase chain reaction (PCR) based qualitative in vitro diagnostic test designed to detect Group B Streptococcus (GBS) nucleic acid from Lim Broth enriched vaginal-rectal specimen swabs obtained from pregnant women.

The objective of this study is to establish the diagnostic accuracy of ARIES GBS Assay through a multi-site, method comparison on prospectively collected, left-over enriched Lim broth specimens.

Diagnostic accuracy will be expressed in terms of clinical sensitivity and specificity.

02

Conditions studied

  • Pregnancy
  • GBS
03

In context

Lead sponsor

Luminex Corporation is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

All comers

Inclusion criteria

  1. An exemption from the requirement for Informed Consent has been granted by the site IRB to include the left-over patient specimens in the study.
  2. Demographic information, including age, geographic location, and number of gestation weeks, is included with the specimen.
  3. The specimen is from a female patient who is at 35 - 37 weeks gestation.
  4. The specimen was collected in unexpired liquid Transport Media (e.g., Liquid Stuart or Liquid Amies).
  5. Enrichment in Lim broth was grown for ≥18 hrs to ≤24 hrs.
  6. The specimen is received in good condition (no leakage or drying of the specimen) and was accepted for testing by the site in accordance with established laboratory procedures.
  7. The volume of the patient specimen after enrichment is sufficient (≥ 1.75mL) for completion of the study.

Exclusion criteria

Exclusion Criteria:

  1. The specimen was collected at a site which is not covered under the study IRB.
  2. The specimen is from a patient for whom demographic data - age, geographic location and/or gestation weeks cannot be obtained.
  3. The specimen was not properly collected, identified, transported, processed or stored according to the instructions provided by the Sponsor.
  4. The specimen was enriched in Lim broth for \<18 hrs or >24 hrs.
  5. A swab specimen that cannot be placed in Lim broth within 4 days of collection.
  6. Inconclusive latex agglutination results - weak agglutination, agglutination that occurs in more than one latex reagent or the results are otherwise considered inconclusive based on established laboratory procedures or the instructions included with the latex agglutination test kit.
  7. Any specimen that was not tested per the complete testing algorithm provided by the Sponsor.
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
918 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Diagnostic accuracy expressed in terms of clinical sensitivity and clinical specificity

    Time frame: Within the first year of sample collection

Secondary outcomes

  1. Comparison of clinical performance per clinical site and per age group

    Time frame: Within the first year of sample collection

07

Study locations

5 sites
  • Sacred Heart Health System
    Pensacola, Florida 32504, United States
  • Detroit Medical Center University Laboratories
    Detroit, Michigan 48201, United States
  • TriCore Reference Laboratories
    Albuquerque, New Mexico 87102, United States
  • Geisinger Medical Laboratories
    Danville, Pennsylvania 17822-0131, United States
  • Baylor Scott & White
    Temple, Texas 76508, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 15, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02497430
Lead sponsor
Luminex Corporation
Responsible party
Sponsor
First posted
Jul 14, 2015
Start date
Mar 2016
Primary completion
Aug 2016
Completion
Aug 2016
Last update
Sep 15, 2016

Study contacts

Ronald D Dunn
study director · Luminex Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion